Jul. 18 at 3:42 PM
$PCRX Valuation Looks Compressed:
PCRX is trading near multi-year lows (~
$22), a big drop from its ~
$80 highs in 2021.
Forward P/E ratio is ~9–10x, well below industry average (15–20x for specialty pharma).
Price-to-Sales ratio is ~1x, which is low for a company with consistent revenue.
Resilient Core Product (EXPAREL):
Still growing (~7% Y/Y in Q1 2025) despite industry headwinds.
No generic competition yet and patent protection until 2029-2031.
Free Cash Flow Positive:
Management expects strong free cash flow for 2025, with lighter capital expenses after recent manufacturing streamlining.
